September 2026 Research Update

Across these studies, the main pattern was that newborn screening accuracy may improve when test results are interpreted with more context rather than a single cutoff for all babies. One large regional program showed fewer false positive screens when repeat samples and birth weight thresholds were used, while a smaller exploratory study suggested a second blood test (mini-puberty hormones) could help clarify whether a positive screen is truly classic congenital adrenal hyperplasia (CAH). [1] [2]

In a population screening program in Piedmont, Italy (90,092 infants), using 17-hydroxyprogesterone (17-OHP) cutoffs adjusted for birth weight plus repeat sampling when indicated reduced false positives across birth weight groups. The program reported eight classic salt-wasting CAH cases and one non-classical CAH case, and it did not find a clear advantage to stratifying by gestational age compared with birth weight criteria. [1]

In a small, single-center retrospective study of 37 infants assessed for suspected 21-hydroxylase deficiency, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels during neonatal mini-puberty were more suppressed in classic disease than in non-classic or false-positive cases. The authors reported high sensitivity and specificity for certain LH and FSH cutoffs, but noted limits such as small numbers, a retrospective design, and the need for validation in larger prospective groups. [2]

For families, this research mainly relates to how newborn screening results might be interpreted and clarified. The large regional screening study supports that adjusting cutoffs for birth weight and using repeat samples can lower the chance of a false alarm, which may reduce avoidable stress and extra testing, but it does not eliminate false positives entirely. The mini-puberty hormone approach is earlier-stage evidence from a small group, so it is best viewed as background research that may inform future screening or follow-up strategies; it remains uncertain how well it works across different hospitals, lab methods, and diverse newborn populations. [1] [2]

Across these studies, one consistent message was that a specific adrenal-related blood marker, 17-hydroxyprogesterone (17-OHP), can be especially helpful for distinguishing certain types of congenital adrenal hyperplasia (CAH) from other conditions with similar symptoms. In contrast, many other hormone measures (including several androgens) overlapped between groups, meaning they were less reliable for telling conditions apart on their own. [3] [4]

In an exploratory study of adult women, early-cycle (early follicular) basal 17-OHP separated nonclassic CAH (due to 21-hydroxylase deficiency) from polycystic ovary syndrome (PCOS) and from healthy controls with perfect discrimination in this cohort. In the same study, anti-Mullerian hormone (AMH) did not differ among groups, and total testosterone and androstenedione were not able to distinguish PCOS from nonclassic CAH because both groups tended to be higher than controls. [3]

In a prospective study of 64 children evaluated for signs such as early puberty changes and faster growth or bone maturation, basal and stimulated 17-OHP levels were higher in those with genetically confirmed CAH than in those where CAH was genetically excluded. Androstenedione was also higher in the CAH group, while testosterone was not clearly different between groups in this cohort. [4]

Two studies focused on expanding or improving hormone testing. One laboratory-focused evaluation compared an automated chemiluminescent test with ELISA for measuring serum 17-OHP in 39 patient samples, finding good precision and strong agreement between methods over a reportable range of 0.10 to 320 ng/mL. [5]

Other work examined additional steroid markers. A diagnostic case-control study measured six so-called androgen backdoor pathway steroids in blood plasma for people with 17-hydroxylase deficiency (a rarer CAH type) and healthy controls, where multi-marker models showed perfect separation in the training set and performed well in a validation cohort. Separately, a retrospective pediatric study in classic 21-hydroxylase deficiency found that 11-ketotestosterone was higher in affected children and higher in those judged to have suboptimal overall control, but it closely tracked with androstenedione and added little extra separation when both were used together. [6] [7]

For patients and caregivers, these papers mainly reinforce that 17-OHP remains a central blood marker for evaluating possible CAH in real-world situations where symptoms can look like PCOS (in women) or early puberty-related changes (in children). They also show that newer steroid measurements and improved lab methods are being studied, but some markers may add limited information beyond existing tests, and several results come from single-center or exploratory studies that may not generalize to all ages, sexes, or CAH types. [3] [4] [5] [6] [7]

Across this group of papers, a consistent message was that genetic testing can often explain the type of congenital adrenal hyperplasia (CAH), but results are not always straightforward. Larger studies in 21-hydroxylase deficiency showed generally strong links between certain gene changes and clinical patterns, while case reports and testing-method papers highlighted how technical pitfalls and complex gene rearrangements can create confusing or even misleading results. [8] [9] [10] [11] [12]

In a Taiwanese cohort of 53 people with classic CAH, the salt-wasting form was diagnosed much earlier than the simple virilizing form, and overall gene results matched the expected clinical severity, although some people did not fit predictions based on the gene change alone. The most common reported gene changes included c.293-13A>G (more often linked with salt-wasting disease) and p.Ile173Asn (more often linked with simple virilizing disease). [8]

In a multicenter study of 131 children in China (119 with 21-hydroxylase deficiency), the salt-wasting group more often had early illness with digestive symptoms and growth issues, while the simple virilizing group more often showed genital virilization and was diagnosed later. The variant called I2G was common and was seen in all children who had two copies of I2G and had the salt-wasting form, while p.I173N was more often seen in simple virilizing disease; certain variant pairs also tracked with differences in bone age or acid-base measurements. [9]

Several papers focused on why the main CAH gene (CYP21A2) can be difficult to test, because it sits in a complicated region of DNA with closely related sequences. One family case report showed that routine sequencing initially made it look like the affected child inherited the same change from both parents, but follow-up testing found this was a false impression caused by a complex gene-conversion event and technical "dropout" during sequencing; the authors used multiple methods to sort out the true inheritance. [10]

A comparative diagnostic study in 20 people found that long-read sequencing could clarify complex CYP21A2 changes that standard methods could miss or misclassify, including defining deletion breakpoints, identifying "2+0" carrier situations (where a deletion can be masked), and separating different chimera types and nearby TNXA/TNXB deletions that matter for recognizing related syndromes. A separate methods paper similarly described long-read sequencing as able to detect single-letter changes, deletions, and gene conversions and to determine which changes are on the same copy of the gene even without parental samples, while also noting practical considerations before wide deployment. [11] [12]

Case reports also illustrated that CAH can be caused by genes other than CYP21A2, and that interpreting new or rare variants may need extra evidence beyond DNA sequencing alone. One neonate with cytochrome P450 oxidoreductase deficiency had three previously unreported POR variants, and the team used RNA-based splicing testing and protein modeling to support reclassifying two variants as likely disease-causing. [13]

Another report described two siblings with lipoid CAH due to STAR gene variants found by clinical exome sequencing; the authors also reviewed European cases and emphasized that the same gene change does not always lead to the same severity. This reinforces that genetic results can guide understanding of cause, but do not perfectly predict day-to-day course for every person. [14]

For patients and caregivers, these papers mainly add context for why genetic reports in CAH can look clear in some families and confusing in others. Larger studies support that, for many people with 21-hydroxylase deficiency, certain gene changes often align with salt-wasting versus simple virilizing patterns, but exceptions occur. Other papers show that complex DNA rearrangements and testing limitations can lead to incomplete or misleading results unless multiple methods (or newer long-read sequencing approaches) are used, and that rarer CAH forms may need additional work to interpret newly found variants. What remains uncertain is how often newer sequencing approaches will change care pathways in routine practice, since much of the evidence here is from method-focused studies and individual case reports rather than large outcome trials.

Across these papers, hydrocortisone-based treatment remained central in congenital adrenal hyperplasia (CAH), with attention to both hormone control and day-to-day safety issues like blood sugar, weight, and blood pressure. Evidence ranged from a small prospective study in women with non-classic CAH to a clinician survey and a single case report, so long-term outcomes and how well results generalize remain uncertain. [15] [16] [17]

In a prospective observational study of 30 women with non-classic CAH, once-daily bedtime modified-release hydrocortisone quickly lowered adrenal hormone markers and most participants with irregular or absent periods returned to regular cycles within 6 months. Among those trying to conceive, many became pregnant within a few months, suggesting that improved overnight hormone control may matter for menstrual and fertility-related outcomes in this specific group. The treatment was reported as well tolerated, with stable blood pressure, fasting glucose, and lipids overall, alongside a small weight decrease and a temporary rise in HbA1c in treatment-naive participants. [15]

A survey of 300 Indian healthcare professionals found oral hydrocortisone was widely prescribed, including for CAH, and many respondents reported seeing side effects such as high blood sugar and weight gain in their practice. Most respondents also reported a perceived need for sustained-release (modified-release) hydrocortisone, showing interest in formulations designed to better match the body's daily cortisol rhythm, although this survey did not test outcomes in patients. [16]

One case report described a newborn with both salt-wasting CAH and very-early-onset polycystic kidney disease, where balancing mineralocorticoid replacement with blood pressure control was challenging. The child developed high blood pressure that improved after reducing the mineralocorticoid dose, highlighting that blood pressure changes can be an important safety issue when CAH care is complicated by kidney disease. Because this was a single patient, it cannot predict what will happen for most families, but it illustrates why multidisciplinary follow-up may be needed in rare combined conditions. [17]

For patients and caregivers, this group of studies mainly adds context about how different hydrocortisone formulations and related steroid medicines may affect hormone levels and practical health concerns (periods, fertility planning, weight, blood sugar, and blood pressure). The strongest direct patient data here come from a small, non-randomized study in women with non-classic CAH, so it helps describe what may be possible but does not prove the same results will occur for everyone or over many years. The survey and the newborn case report are useful for understanding real-world prescribing concerns and complex monitoring needs, but they do not establish which treatment is best. [15] [16] [17]

Across this group of papers, long-term outcomes in congenital adrenal hyperplasia (CAH) looked different by age and body system. Early life stood out for heavier hospital needs, while later concerns included growth and puberty patterns, and reproductive health issues in some people. Evidence ranged from a large nationwide hospital dataset to smaller single-center studies and one case report, so not every result will apply to every person. [18] [19] [20] [21] [22]

In a nationwide Swiss hospital analysis, hospitalizations that involved CAH were most common in neonates, infants, and young children, and endocrine or metabolic problems were the most common admission reason. These CAH-related hospitalizations also showed a higher overall burden of other health problems and a higher chance of intensive care unit (ICU) admission compared with non-CAH hospitalizations (odds ratio 1.55), with the biggest differences in the youngest ages. In plain terms, severe in-hospital events were more likely during hospital stays in early life when CAH was part of the picture. [18]

A 30-year, single-center review of 63 people with CAH reported that near-final adult height was below population norms, with the salt-wasting group starting off shorter in early measurements. Higher hydrocortisone exposure was linked to poorer height outcomes, and the study pointed to ages around 6 to 10 years as a period when bone maturation sped up and growth patterns shifted. In plain language, the years before and during early grade-school age may be a key time when growth can be affected, and steroid exposure level appeared to matter. [19]

In a small single-center study of 23 adult men with CAH due to 21-hydroxylase deficiency, about half had testicular adrenal rest tumors (11 of 23). These tumors were linked with higher levels of hormone signals of adrenal stimulation (ACTH) and higher 17-hydroxyprogesterone, and were more common in people with more severe genetic forms and earlier diagnosis; changes in steroid treatment did not show a clear and consistent pattern of tumor shrinkage. In plain terms, these testicular growths were common in this adult clinic population and seemed connected to long-standing disease severity and hormone control markers, but their course over time was not predictable from treatment changes in this study. [20]

A German guideline update covering differences of sex development (DSD) stated that gonadal tumor risk depends strongly on the specific DSD condition, and is highest when there is Y-chromosome material and underdeveloped (dysgenetic) gonads. The review described gonadal tumor risk as substantially lower in CAH than in the highest-risk DSD groups, and emphasized individualized risk assessment and long-term specialized follow-up. In plain language, compared with some other DSD conditions, CAH was placed in a lower-risk category for gonadal tumors in this guideline discussion. [21]

One case report described a 35-year-old person with a less common CAH type (11 beta-hydroxylase deficiency) that had gone unrecognized into adulthood, where imaging found large benign fatty adrenal tumors (myelolipomas) along with enlarged adrenal glands. The report also described high blood pressure and kidney protein loss, plus reproductive anatomy findings that were unexpected for the sex in which the person was raised, leading to multidisciplinary follow-up. Because this is a single patient, it mainly illustrates that unrecognized CAH can be linked with significant adrenal growths and long-term complications. [22]

For patients and caregivers, these studies add context about which long-term issues have been documented in research: higher-intensity hospital care needs are most visible in the youngest children, while later concerns may include growth and puberty patterns, and in some males, testicular adrenal rest tumors that can relate to fertility. The guideline paper also suggests that, within the broader DSD landscape, CAH is generally considered lower risk for gonadal tumors than some other conditions, though individual factors still matter. Uncertainties remain because several results come from single-center cohorts and one-person reports, and they cannot predict an individual person's future health course. [18] [19] [20] [21] [22]

Across this group of studies, mental health and family experiences in congenital adrenal hyperplasia (CAH) looked mixed but consistently challenging for some people. A review of females with classical CAH described psychological and sexual-health concerns and lower quality of life than in healthy females, although the findings varied across studies. A separate parent survey linked higher caregiver burnout with more rejecting or cold parenting behaviors, suggesting family stress may affect day-to-day relationships in some households. [23] [24]

In a systematic review of 11 studies including 523 females with classical CAH (21-hydroxylase deficiency), participants had lower quality of life than healthy controls; one included study reported higher rates of anxiety and social phobia, but these differences were not statistically significant. The review also described concerns tied to reproductive and sexual well-being, including lower sexual satisfaction, distress about genital appearance, and pain with sex or pelvic pain, but the studies were small and used different measures, making firm conclusions difficult. [23]

The same review reported higher rates of atypical gender identity and gender dysphoria in females with classical CAH than in healthy controls, alongside reports of stigma-related secrecy and difficulties with dating or intimate relationships in some studies. Because most included studies were cross-sectional and came largely from Western settings, it remains unclear how these experiences vary across cultures and healthcare systems. [23]

In an exploratory cross-sectional study of 60 parents of 45 children with classical CAH in Central Java, Indonesia, higher parental burnout scores were linked to higher overall rejection, including more hostility and indifference. Fathers reported more rejection and emotional coldness than mothers, and lower education levels were linked to higher rejection or hostility; later onset of CAH was linked to higher undifferentiated rejection. The authors noted these early results should not yet be used to guide counseling without further study. [24]

For patients and caregivers, these papers mainly add background evidence about the kinds of emotional and relationship difficulties that some families and females with classical CAH report, rather than changing medical care. The review suggests that anxiety, social fears, sexual well-being, and quality of life may be areas of concern for some individuals, but the evidence is uneven because studies were small and not designed to prove cause and effect. The parent survey suggests caregiver burnout may go along with more strained parent-child interactions, but it cannot show whether burnout causes rejection or which supports would help, so more research is still needed in different communities and age groups. [23] [24]

One small retrospective study looked at whether a structured, multidisciplinary transition from pediatric to adult endocrine care changes follow-up patterns or CAH health measures compared with a non-structured transfer. Overall, both groups stayed in adult follow-up and had similar hormone-related and clinical outcomes over the study periods, but the study was too small to rule out meaningful differences. [25]

In 29 patients with CAH at a single center in Turkiye, continuity-of-care measures (such as care gaps and visit intervals) were not significantly different between structured and non-structured transition pathways. Hormone markers and clinical measures tracked by the clinic were also similar between groups, and treatment approaches became more varied after transfer in both pathways. Two people in the structured group had emergency visits related to adrenal crisis during follow-up, while none were reported in the non-structured group, but numbers were very small. [25]

For families thinking about the pediatric-to-adult handoff, this study suggests that in one clinic, a structured transition program did not clearly outperform a non-structured transfer on measured follow-up and CAH outcomes. Because it was a small, retrospective study from a single center, it may not reflect what happens in other healthcare systems or with different transition resources. More research is needed to understand which parts of transition support matter most to patients and caregivers, including effects on daily life, confidence in self-management, and emotional well-being. [25]